The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value
Language English Country Germany Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Ki-1 Antigen blood MeSH
- Biomarkers blood MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- CD40 Ligand blood MeSH
- Adolescent MeSH
- Lupus Nephritis blood diagnosis MeSH
- Aged MeSH
- Lupus Erythematosus, Systemic blood diagnosis MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Ki-1 Antigen MeSH
- Biomarkers MeSH
- CD40 Ligand MeSH
CD30/CD30L and CD40/CD40L are molecules from the tumor necrosis factor (TNF) superfamily. They have a major effect on communications between the B and T cells, which leads to control of maturation, proliferation, and apoptosis of those cells. The aim of this study was to compare the levels of a soluble form of CD30 (sCD30) and a soluble ligand CD40 (sCD40L) in patients with systemic lupus erythematosus (SLE) (n=65) and healthy controls (sCD30 n=20, sCD40L n=10) with other parameters of SLE activity. Patients were divided into subgroups according to presence or absence of lupus nephritis (LN; 33 with LN, 32 without LN). The serum levels of selected parameters were assessed also in the subgroups with low active disease characterized by European Lupus Activity Measure (ECLAM) at most 3(n=29) and active disease with ECLAM more than 3 (n=36). The serum levels of sCD30 were 66.0+/-40.2 UI/ml in the whole group. The mean serum levels were 60.0+/-45.2 UI/ml in the subgroups with LN, 67.1+/-38.9 UI/ml in the subgroup without LN, 80.2+/-51.9 UI/ml in the subgroup with active disease, 55.4+/-24.1 UI/ml in the subgroup with low active disease, and finally, 40.1+/-19.2 U/ml in the controls. Significant differences were found between the SLE patients and controls (p=0.0001) and between the active and nonactive groups (p=0.002). A correlation was found between levels of CD30 and ECLAM (r=0.25, p
See more in PubMed
Clin Rheumatol. 2001;20(5):337-44 PubMed
Blood. 2000 Dec 15;96(13):4307-12 PubMed
J Clin Invest. 2004 Sep;114(5):679-88 PubMed
AMA Arch Derm Syphilol. 1953 Aug;68(2):119-28 PubMed
Acta Med Okayama. 2003 Dec;57(6):267-77 PubMed
Clin Exp Rheumatol. 1992 Sep-Oct;10(5):549-54 PubMed
Mol Aspects Med. 1996 Oct;17(5):455-509 PubMed
Arthritis Rheum. 1992 Jun;35(6):630-40 PubMed
J Clin Invest. 1999 Oct;104(7):947-55 PubMed
J Clin Invest. 1996 Aug 1;98(3):826-37 PubMed
Clin Rheumatol. 2006 Jul;25(4):532-6 PubMed
J Rheumatol. 2001 Jan;28(1):95-101 PubMed
Adv Immunol. 1985;37:151-216 PubMed
Blood. 1995 Jan 1;85(1):1-14 PubMed
Ther Apher Dial. 2005 Feb;9(1):64-8 PubMed
Arthritis Res. 2002;4 Suppl 3:S279-93 PubMed
J Clin Invest. 2006 Mar;116(3):724-34 PubMed
Arthritis Rheum. 1982 Nov;25(11):1271-7 PubMed
Rheumatology (Oxford). 2003 Jan;42(1):117-22 PubMed
J Autoimmun. 2006 May;26(3):165-71 PubMed
Clin Exp Rheumatol. 1995 May-Jun;13(3):339-43 PubMed
Ann N Y Acad Sci. 2005 Jun;1051:433-41 PubMed
Lupus. 1999;8(8):632-7 PubMed
